US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pasithea Therapeutics Corp.

0.8310

-0.1290-13.44%

Pre-market: 0.8200-0.0110-1.32%07:35 EDT

Volume:2.06M

Turnover:1.78M

Market Cap:5.43M

PE:-0.07

High:0.9695

Open:0.9500

Low:0.7970

Close:0.9600

Loading ...

Overview Company News Filings

BRIEF-Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering

Pasithea Therapeutics Prices $5 Million Public Offering

MT Newswires Live

Pasithea Therapeutics 3.57M share Secondary priced at $1.40

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

THOMSON REUTERS

Pasithea- Pas-004 Demonstrated Clinically Meaningful Reductions in Perk Levels at Dose Levels That Are Well-Tolerated, Safe, With No Rash Observed

THOMSON REUTERS

Pasithea Therapeutics - Positive Interim Pharmacodynamic Data From Ongoing Phase 1 Trial of Pas-004 in Advanced Cancer Patients

THOMSON REUTERS

BRIEF-Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing

Pasithea Therapeutics Files for Offering up to 3.2 Mln Common Shares Together With Warrants - SEC Filing

THOMSON REUTERS

Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004

Pasithea Therapeutics Corp - Enrollment Expected to Complete by End of 2025

THOMSON REUTERS

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 From Its Phase 1 Trial of Pas-004 in Advanced Cancer Patients

THOMSON REUTERS

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial

MT Newswires Live

BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer

Pasithea Therapeutics Corp - No Dose-Limiting Toxicities (Dlt's) or Rash Observed to Date

THOMSON REUTERS

Pasithea Therapeutics Corp - Src Recommended That Trial Escalate to Next Dose Level of 30Mg Capsule

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KTTA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KTTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTA\",,,,,undefined,":{"symbol":"KTTA","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp.","latestPrice":0.831,"timestamp":1746820800000,"preClose":0.96,"halted":0,"volume":2062403,"hourTrading":{"tag":"盘前","latestPrice":0.82,"preClose":0.831,"latestTime":"07:35 EDT","volume":12147,"amount":10098.780998490001,"timestamp":1747049754223},"delay":0,"floatShares":6416400,"shares":6529299,"eps":-12.685715,"marketStatus":"Pre-Mkt","change":-0.129,"latestTime":"05-12 07:40:08 EDT","open":0.95,"high":0.9695,"low":0.797,"amount":1779712.865003,"amplitude":0.179688,"askPrice":0.84,"askSize":1510,"bidPrice":0.82,"bidSize":1141,"shortable":0,"etf":0,"ttmEps":-12.685715,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747056600000},"marketStatusCode":1,"adr":0,"listingDate":1628654400000,"exchange":"NASDAQ","adjPreClose":0.831,"preHourTrading":{"tag":"盘前","latestPrice":0.82,"preClose":0.831,"latestTime":"07:35 EDT","volume":12147,"amount":10098.780998490001,"timestamp":1747049754223},"postHourTrading":{"tag":"盘后","latestPrice":0.7901,"preClose":0.831,"latestTime":"19:59 EDT","volume":71432,"amount":57796.6941,"timestamp":1746835168624},"volumeRatio":0.04429606645704189},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTA\",,,,,undefined,":{"symbol":"KTTA","floatShares":6416400,"roa":"-42.23%","roe":"-72.83%","lyrEps":-12.685715,"volumeRatio":0.04429606645704189,"shares":6529299,"dividePrice":0,"high":0.9695,"amplitude":0.179688,"preClose":0.96,"low":0.797,"week52Low":0.797,"pbRate":"0.37","psRate":"11.15","week52High":7.5,"institutionHeld":0,"latestPrice":0.831,"committee":-0.139193,"eps":-12.685715,"divideRate":0,"volume":2062403,"delay":0,"ttmEps":-12.685715,"open":0.95,"prevYearClose":3.15,"prevWeekClose":0.831,"prevMonthClose":1.66,"prevQuarterClose":1.3,"fiveDayClose":1.4,"twentyDayClose":1.6,"sixtyDayClose":1.43},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KTTA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533433654","title":"BRIEF-Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2533433654","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533433654?lang=en_us&edition=fundamental","pubTime":"2025-05-07 00:18","pubTimestamp":1746548292,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Announces Pricing Of $5 Million Public OfferingMay 6 (Reuters) - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERINGSource text: ID:nGNX58PWjJFurther company coverage: KTTA.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE2EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2533065947","title":"Pasithea Therapeutics Prices $5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2533065947","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533065947?lang=en_us&edition=fundamental","pubTime":"2025-05-06 23:38","pubTimestamp":1746545880,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics  said Tuesday it priced a $5 million public offering consisting of nearly 3.6 million common shares, or pre-funded warrants, at $1.40 per share.The offering includes series C warrants, which expire in five years, and series D warrants, which expire in 18 months, both exercisable at $1.40 per share.The offering is expected to close around Wednesday, pending the fulfillment of customary closing conditions.The company plans to use the proceeds for general corporate purposes such as research, clinical trials, technology development, potential acquisitions, and working capital, the company said.Shares of the biotechnology company rose more than 35% in recent Tuesday trading.Price: 1.92, Change: +0.50, Percent Change: +35.21","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KTTA","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2533659448","title":"Pasithea Therapeutics 3.57M share Secondary priced at $1.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2533659448","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533659448?lang=en_us&edition=fundamental","pubTime":"2025-05-06 23:35","pubTimestamp":1746545733,"startTime":"0","endTime":"0","summary":"The gross proceeds to the company from the offering are expected to be approximately $5M, before deducting the placement agent’s fees and other off...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-3-57m-share-secondary-priced-at-1-40?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-3-57m-share-secondary-priced-at-1-40?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KTTA","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2533550826","title":"Pasithea Therapeutics Announces Pricing of $5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2533550826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533550826?lang=en_us&edition=fundamental","pubTime":"2025-05-06 23:10","pubTimestamp":1746544214,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE2EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2533925686","title":"Pasithea- Pas-004 Demonstrated Clinically Meaningful Reductions in Perk Levels at Dose Levels That Are Well-Tolerated, Safe, With No Rash Observed","url":"https://stock-news.laohu8.com/highlight/detail?id=2533925686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533925686?lang=en_us&edition=fundamental","pubTime":"2025-05-06 19:04","pubTimestamp":1746529444,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE1UO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2533686590","title":"Pasithea Therapeutics - Positive Interim Pharmacodynamic Data From Ongoing Phase 1 Trial of Pas-004 in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2533686590","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533686590?lang=en_us&edition=fundamental","pubTime":"2025-05-06 19:04","pubTimestamp":1746529444,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE1UO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2532000524","title":"BRIEF-Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2532000524","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532000524?lang=en_us&edition=fundamental","pubTime":"2025-05-02 00:21","pubTimestamp":1746116464,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC FilingMay 1  - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS FILES FOR OFFERING UP TO 3.2 MILLION COMMON SHARES TOGETHER WITH WARRANTS - SEC FILINGSource text: [ID:n0001213900-25-038088]Further company coverage: KTTA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nFWN3R92EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2532070698","title":"Pasithea Therapeutics Files for Offering up to 3.2 Mln Common Shares Together With Warrants - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2532070698","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532070698?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:30","pubTimestamp":1746106216,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nFWN3R92EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2531789494","title":"Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2531789494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531789494?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:18","pubTimestamp":1745925516,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (KTTA) announced the Company has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-completes-enrollment-in-cohort-6-of-phase-1-trial-of-pas-004?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-completes-enrollment-in-cohort-6-of-phase-1-trial-of-pas-004?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2531890227","title":"Pasithea Therapeutics Corp - Enrollment Expected to Complete by End of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531890227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531890227?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924520,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA24WKY2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2531786615","title":"Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 From Its Phase 1 Trial of Pas-004 in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2531786615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531786615?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924520,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA24WKY2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA","KTTAW"],"gpt_icon":0},{"id":"2531314781","title":"Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2531314781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531314781?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924520,"startTime":"0","endTime":"0","summary":"MIAMI, April 29, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1  and other MAPK pathway driven cancer indications, today announced the Company has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of PAS-004.The ongoing Phase 1 clinical trial is a multi-center, open-label, dose escalation 3+3 study design to evaluate the safety, tolerability, pharmacokinetics , pharmacodynamics , and preliminary efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-announces-completion-enrollment-110200697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU1169589451.USD","IE00B7SZL793.SGD","PK","KTTA","BK4135","LENZ","LU1169590202.USD","BK4157","PD","BK4023","IE0031619046.USD","BK4218","BK4007","IE00B66KJ199.SGD","KTTAW","BK4181","CNS","AEIS","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENVB","AGNPF","MNMD","GHRS","CMND","PSYGF","MYCOF","SEEL","MIRA","CYBN","BK4547","RLMD","ALID","FLHLF","NUMIF","QNTM","CMPS","OPTHF","SILO","KTTA","IXHL","BK4202","SPRC","SNPX","ATAI","MDXXF","BK4168","PHRRF","PBM","BK4539","ENTBF","BK4139","NRXP","BETRF","DRUG","BK4007","RVVTF"],"gpt_icon":0},{"id":"2529607368","title":"Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529607368","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529607368?lang=en_us&edition=fundamental","pubTime":"2025-04-24 19:02","pubTimestamp":1745492520,"startTime":"0","endTime":"0","summary":"Poster presentation on Monday, June 2, 2025 from 1:30 – 4:30 PM CDT at the ASCO Annual Meeting. MIAMI, April 24, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1  and other MAPK pathway driven indications, today announced the acceptance of an abstract for a poster prenstation at the Annual Meeting of the American Society for Clinical Oncology  taking place May 30 – June 3, 2025, in Chicago, Illinois.The Company will present updated interim clinical data from its onging Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid tumors.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-present-updated-data-110200343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","LU1169589451.USD","LU1169590202.USD","PK","PD","BK4135","IE00B66KJ199.SGD","CNS","BK4157","BK4218","BK4007","KTTAW","IE00B19Z4B17.USD","BK4181","BK4023","IE0031619046.USD","BK4139","KTTA","AEIS","LENZ"],"gpt_icon":0},{"id":"2526659586","title":"Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2526659586","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526659586?lang=en_us&edition=fundamental","pubTime":"2025-04-10 22:13","pubTimestamp":1744294382,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics  said Thursday that the external Safety Review Committee recommended that the company's phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor, in advanced cancer should proceed to cohort 6, 30mg capsules, without any modification.The recommendation was based on the review of the safety data from three patients from cohort 5 and the absence of any dose limiting toxicities, or DLT, the biotechnology company said.During the DLT period, no rash was observed to date in any of the first 19 patients in either capsule or tablet formulation of PAS-004. Rash is a common adverse event that is observed at low doses with competitor MEK inhibitors, Pasithea said.Shares were up 50% in early Thursday trading.Price: 1.62, Change: +0.54, Percent Change: +50.00","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z4B17.USD","BK4007","IE00B66KJ199.SGD","BK6088","IE00B7SZL793.SGD","BK4157","LENZ","BLZ.SI","BK6522","BK4139","AEIS","KTTA","IE0031619046.USD"],"gpt_icon":0},{"id":"2526554735","title":"BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526554735","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526554735?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:12","pubTimestamp":1744283522,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced CancerApril 10 (Reuters) - Pasithea Therapeut","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN25E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2526846554","title":"Pasithea Therapeutics Corp - No Dose-Limiting Toxicities (Dlt's) or Rash Observed to Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2526846554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526846554?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:02","pubTimestamp":1744282923,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN25E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2526548425","title":"Pasithea Therapeutics Corp - Src Recommended That Trial Escalate to Next Dose Level of 30Mg Capsule","url":"https://stock-news.laohu8.com/highlight/detail?id=2526548425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526548425?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:02","pubTimestamp":1744282923,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN25E:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KTTA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-24","symbol":"KTTA","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-2.41},{"market":"US","date":"2024-08-13","symbol":"KTTA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-3.71},{"market":"US","date":"2024-05-14","symbol":"KTTA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-3.7},{"market":"US","date":"2024-03-28","symbol":"KTTA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711598400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-01-02","symbol":"KTTA","defaultRemindTime":1704205800000,"type":"split","dateTimestamp":1704171600000,"forFactor":20,"toFactor":1,"ratio":20}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KTTA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KTTA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KTTA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KTTA","date":"2025-05-09","current":-0.417852,"percent":0.729425,"low":-1093.683193,"twenty":-8.874587,"median":-0.792023,"eighty":-0.321722,"high":-0.082689,"avg":-39.974095,"sd":150.793154,"marketCap":5810061},"quantilePoints":[{"date":"2021-08-13","current":-1093.683193,"twenty":-1093.683193,"median":-1093.683193,"eighty":-1093.683193,"marketCap":67235268},{"date":"2021-09-17","current":-669.104496,"twenty":-1093.683193,"median":-756.194287,"eighty":-671.674393,"marketCap":41133868},{"date":"2021-09-24","current":-626.621673,"twenty":-1093.683193,"median":-671.674393,"eighty":-632.994101,"marketCap":38522194},{"date":"2021-10-01","current":-609.628538,"twenty":-891.189849,"median":-656.359653,"eighty":-608.804372,"marketCap":37477524},{"date":"2021-10-08","current":-556.525018,"twenty":-729.430106,"median":-641.490663,"eighty":-578.616078,"marketCap":34212932},{"date":"2021-10-15","current":-632.994095,"twenty":-687.639563,"median":-626.621673,"eighty":-571.393991,"marketCap":38913945},{"date":"2021-10-22","current":-571.393991,"twenty":-671.674393,"median":-609.628538,"eighty":-571.393991,"marketCap":35127017},{"date":"2021-10-29","current":-601.13197,"twenty":-670.132455,"median":-607.568124,"eighty":-571.393991,"marketCap":36955189},{"date":"2021-11-05","current":-537.407736,"twenty":-661.45759,"median":-596.894317,"eighty":-566.296057,"marketCap":33037678},{"date":"2021-11-12","current":-548.02845,"twenty":-653.810678,"median":-586.262981,"eighty":-556.525018,"marketCap":33690597},{"date":"2021-11-19","current":-10.979296,"twenty":-648.287908,"median":-575.642283,"eighty":-545.904304,"marketCap":31303839},{"date":"2021-11-26","current":-18.576783,"twenty":-642.340318,"median":-572.456064,"eighty":-536.133248,"marketCap":52965567},{"date":"2021-12-03","current":-21.49554,"twenty":-635.54307,"median":-571.393991,"eighty":-511.493207,"marketCap":61287438},{"date":"2021-12-10","current":-17.503511,"twenty":-631.294785,"median":-567.145715,"eighty":-26.651141,"marketCap":49905485},{"date":"2021-12-17","current":-11.361928,"twenty":-627.896161,"median":-558.649148,"eighty":-21.219169,"marketCap":32394789},{"date":"2021-12-23","current":-15.430727,"twenty":-624.92236,"median":-556.525018,"eighty":-19.683773,"marketCap":43995625},{"date":"2021-12-31","current":-13.588252,"twenty":-616.425792,"median":-549.090515,"eighty":-17.135016,"marketCap":38742416},{"date":"2022-01-07","current":-11.438698,"twenty":-609.628538,"median":-545.904304,"eighty":-14.877985,"marketCap":32613672},{"date":"2022-01-14","current":-10.59423,"twenty":-609.216455,"median":-536.345663,"eighty":-14.064224,"marketCap":30205951},{"date":"2022-01-21","current":-9.596223,"twenty":-607.568124,"median":-527.849104,"eighty":-13.434712,"marketCap":27360463},{"date":"2022-01-28","current":-8.598216,"twenty":-601.13197,"median":-505.545611,"eighty":-11.515468,"marketCap":24514975},{"date":"2022-02-04","current":-9.135604,"twenty":-599.00784,"median":-30.170526,"eighty":-11.361928,"marketCap":26047161},{"date":"2022-02-11","current":-9.442684,"twenty":-594.780793,"median":-25.717878,"eighty":-10.979296,"marketCap":26922696},{"date":"2022-02-18","current":-8.367907,"twenty":-594.759548,"median":-21.265231,"eighty":-10.238077,"marketCap":23858324},{"date":"2022-02-25","current":-7.830518,"twenty":-587.962294,"median":-19.883375,"eighty":-9.964718,"marketCap":22326138},{"date":"2022-03-04","current":-8.674986,"twenty":-582.86436,"median":-18.576783,"eighty":-9.442684,"marketCap":24733859},{"date":"2022-03-11","current":-9.212374,"twenty":-576.916767,"median":-17.273201,"eighty":-9.35056,"marketCap":26266045},{"date":"2022-03-18","current":-10.210381,"twenty":-575.642283,"median":-15.430727,"eighty":-9.35056,"marketCap":29111533},{"date":"2022-03-25","current":-10.287151,"twenty":-573.942966,"median":-14.739799,"eighty":-9.365914,"marketCap":29330417},{"date":"2022-04-01","current":-13.65563,"twenty":-571.81882,"median":-14.35595,"eighty":-9.42733,"marketCap":29680798},{"date":"2022-04-08","current":-13.126342,"twenty":-571.393991,"median":-13.905179,"eighty":-9.442684,"marketCap":28530380},{"date":"2022-04-14","current":-14.290775,"twenty":-571.393991,"median":-13.751639,"eighty":-9.488745,"marketCap":31061300},{"date":"2022-04-22","current":-12.279481,"twenty":-570.119513,"median":-13.588252,"eighty":-9.565515,"marketCap":26689710},{"date":"2022-04-29","current":-12.702912,"twenty":-567.995373,"median":-13.285128,"eighty":-9.596223,"marketCap":27610045},{"date":"2022-05-06","current":-10.967906,"twenty":-567.145715,"median":-13.126342,"eighty":-9.596223,"marketCap":23838973},{"date":"2022-05-13","current":-9.630924,"twenty":-565.871227,"median":-13.073413,"eighty":-9.617044,"marketCap":20933015},{"date":"2022-05-20","current":-6.517075,"twenty":-561.198116,"median":-13.020484,"eighty":-9.488745,"marketCap":20842597},{"date":"2022-05-27","current":-6.082361,"twenty":-557.37467,"median":-12.649983,"eighty":-9.335206,"marketCap":19452314},{"date":"2022-06-03","current":-7.244512,"twenty":-556.525018,"median":-12.385339,"eighty":-9.289144,"marketCap":23169050},{"date":"2022-06-10","current":-7.427281,"twenty":-556.525018,"median":-12.385339,"eighty":-9.135604,"marketCap":23753574},{"date":"2022-06-17","current":-7.427281,"twenty":-553.976043,"median":-12.279481,"eighty":-8.936003,"marketCap":23753574},{"date":"2022-06-24","current":-7.093053,"twenty":-549.727754,"median":-12.279481,"eighty":-8.69034,"marketCap":22684663},{"date":"2022-07-01","current":-7.281648,"twenty":-547.603621,"median":-11.976086,"eighty":-8.306491,"marketCap":23287818},{"date":"2022-07-08","current":-7.791364,"twenty":-545.904304,"median":-11.515468,"eighty":-8.191854,"marketCap":24917965},{"date":"2022-07-15","current":-9.147016,"twenty":-545.904304,"median":-11.435659,"eighty":-8.082629,"marketCap":29253549},{"date":"2022-07-22","current":-9.432861,"twenty":-543.780158,"median":-11.361928,"eighty":-8.166979,"marketCap":30167723},{"date":"2022-07-29","current":-9.473696,"twenty":-537.407736,"median":-11.086562,"eighty":-8.191854,"marketCap":30298319},{"date":"2022-08-05","current":-10.127054,"twenty":-535.28359,"median":-10.967906,"eighty":-8.214367,"marketCap":32387858},{"date":"2022-08-12","current":-10.780413,"twenty":-533.159461,"median":-10.725706,"eighty":-8.291137,"marketCap":34477398},{"date":"2022-08-19","current":-6.949802,"twenty":-522.538747,"median":-10.59423,"eighty":-8.082629,"marketCap":35642748},{"date":"2022-08-26","current":-6.194955,"twenty":-520.414601,"median":-10.479076,"eighty":-7.830518,"marketCap":31771438},{"date":"2022-09-02","current":-5.986721,"twenty":-505.545611,"median":-10.363921,"eighty":-7.791364,"marketCap":30703491},{"date":"2022-09-09","current":-6.455247,"twenty":-497.049053,"median":-10.238077,"eighty":-7.500098,"marketCap":33106373},{"date":"2022-09-16","current":-6.559364,"twenty":-125.08671,"median":-10.210381,"eighty":-7.427135,"marketCap":33640346},{"date":"2022-09-23","current":-6.194955,"twenty":-28.696546,"median":-10.208724,"eighty":-7.354465,"marketCap":31771438},{"date":"2022-09-30","current":-6.559364,"twenty":-26.296891,"median":-10.091948,"eighty":-7.310774,"marketCap":33640346},{"date":"2022-10-07","current":-6.403188,"twenty":-25.76283,"median":-9.980072,"eighty":-7.237376,"marketCap":32839386},{"date":"2022-10-14","current":-6.507305,"twenty":-25.410799,"median":-9.903302,"eighty":-7.06116,"marketCap":33373360},{"date":"2022-10-21","current":-5.518195,"twenty":-22.263238,"median":-9.630924,"eighty":-6.814917,"marketCap":28300609},{"date":"2022-10-28","current":-5.622312,"twenty":-21.127045,"median":-9.596223,"eighty":-6.757186,"marketCap":28834583},{"date":"2022-11-04","current":-6.159301,"twenty":-20.175099,"median":-9.555365,"eighty":-6.611422,"marketCap":31588583},{"date":"2022-11-11","current":-5.988209,"twenty":-19.837313,"median":-9.494114,"eighty":-6.559364,"marketCap":30711122},{"date":"2022-11-18","current":-3.744034,"twenty":-19.683773,"median":-9.442684,"eighty":-6.515619,"marketCap":30658474},{"date":"2022-11-25","current":-3.607588,"twenty":-19.007296,"median":-9.432861,"eighty":-6.507305,"marketCap":29541174},{"date":"2022-12-02","current":-3.679026,"twenty":-18.521192,"median":-9.392026,"eighty":-6.455247,"marketCap":30126148},{"date":"2022-12-09","current":-3.500432,"twenty":-17.895759,"median":-9.365914,"eighty":-6.382365,"marketCap":28663714},{"date":"2022-12-16","current":-2.714621,"twenty":-17.22714,"median":-9.310356,"eighty":-6.278248,"marketCap":22229002},{"date":"2022-12-23","current":-2.062755,"twenty":-16.305902,"median":-9.289144,"eighty":-6.245813,"marketCap":16891117},{"date":"2022-12-30","current":-2.292069,"twenty":-15.661036,"median":-9.289144,"eighty":-6.194955,"marketCap":18768883},{"date":"2023-01-06","current":-2.309214,"twenty":-15.369311,"median":-9.229503,"eighty":-6.161226,"marketCap":18909276},{"date":"2023-01-13","current":-2.488168,"twenty":-15.06293,"median":-9.179695,"eighty":-6.142896,"marketCap":20374665},{"date":"2023-01-20","current":-2.447802,"twenty":-14.820063,"median":-9.135604,"eighty":-6.090838,"marketCap":20044125},{"date":"2023-01-27","current":-2.489236,"twenty":-14.816569,"median":-8.982065,"eighty":-6.045239,"marketCap":20383410},{"date":"2023-02-03","current":-2.421728,"twenty":-14.663029,"median":-8.86691,"eighty":-5.986721,"marketCap":19830610},{"date":"2023-02-10","current":-2.088826,"twenty":-14.35595,"median":-8.697833,"eighty":-5.934662,"marketCap":17104603},{"date":"2023-02-17","current":-2.096687,"twenty":-14.290775,"median":-8.636601,"eighty":-5.726429,"marketCap":17168979},{"date":"2023-02-24","current":-1.752716,"twenty":-14.158667,"median":-8.534493,"eighty":-5.622312,"marketCap":14352331},{"date":"2023-03-03","current":-1.780577,"twenty":-14.064224,"median":-8.291137,"eighty":-5.171792,"marketCap":14580470},{"date":"2023-03-10","current":-1.729249,"twenty":-13.818964,"median":-8.20311,"eighty":-3.679026,"marketCap":14160167},{"date":"2023-03-17","current":-1.535904,"twenty":-13.745731,"median":-8.082629,"eighty":-3.607588,"marketCap":12576935},{"date":"2023-03-24","current":-1.428748,"twenty":-13.672862,"median":-7.885734,"eighty":-3.570084,"marketCap":11699475},{"date":"2023-03-31","current":-1.339451,"twenty":-13.601728,"median":-7.830518,"eighty":-3.500432,"marketCap":10968258},{"date":"2023-04-05","current":-1.428391,"twenty":-13.526836,"median":-7.810941,"eighty":-3.465357,"marketCap":11696550},{"date":"2023-04-14","current":-0.749882,"twenty":-13.39605,"median":-7.718547,"eighty":-2.874212,"marketCap":10450696},{"date":"2023-04-21","current":-0.836681,"twenty":-13.316885,"median":-7.500098,"eighty":-2.62461,"marketCap":11660364},{"date":"2023-04-28","current":-0.656147,"twenty":-13.211028,"median":-7.436975,"eighty":-2.543242,"marketCap":9144359},{"date":"2023-05-05","current":-0.581159,"twenty":-13.126342,"median":-7.426917,"eighty":-2.49638,"marketCap":8099289},{"date":"2023-05-12","current":-0.674894,"twenty":-13.126342,"median":-7.354465,"eighty":-2.482807,"marketCap":9405626},{"date":"2023-05-18","current":-0.558853,"twenty":-13.126342,"median":-7.354465,"eighty":-2.427442,"marketCap":8885704},{"date":"2023-05-26","current":-0.600098,"twenty":-13.126342,"median":-7.33626,"eighty":-2.358077,"marketCap":9541485},{"date":"2023-06-02","current":-0.575285,"twenty":-13.062827,"median":-7.281648,"eighty":-2.303499,"marketCap":9146971},{"date":"2023-06-09","current":-0.79531,"twenty":-13.020484,"median":-7.244512,"eighty":-2.280424,"marketCap":12645342},{"date":"2023-06-16","current":-0.761131,"twenty":-13.020484,"median":-7.134559,"eighty":-2.147122,"marketCap":12101905},{"date":"2023-06-23","current":-0.709863,"twenty":-12.978141,"median":-7.063199,"eighty":-2.090973,"marketCap":11286751},{"date":"2023-06-30","current":-0.788737,"twenty":-12.808769,"median":-6.990382,"eighty":-2.071684,"marketCap":12540835},{"date":"2023-07-07","current":-0.838033,"twenty":-12.724083,"median":-6.819656,"eighty":-2.046396,"marketCap":13324637},{"date":"2023-07-14","current":-0.755052,"twenty":-12.639397,"median":-6.767598,"eighty":-1.946312,"marketCap":12005237},{"date":"2023-07-21","current":-0.974419,"twenty":-12.512368,"median":-6.767598,"eighty":-1.782717,"marketCap":15493156},{"date":"2023-07-28","current":-0.971133,"twenty":-12.385339,"median":-6.650466,"eighty":-1.757289,"marketCap":15440903},{"date":"2023-08-04","current":-0.973269,"twenty":-12.385339,"median":-6.611422,"eighty":-1.737636,"marketCap":15474868},{"date":"2023-08-11","current":-1.029301,"twenty":-12.385339,"median":-6.559364,"eighty":-1.647346,"marketCap":16365772},{"date":"2023-08-18","current":-0.922144,"twenty":-12.385339,"median":-6.559364,"eighty":-1.54019,"marketCap":15680815},{"date":"2023-08-25","current":-0.936135,"twenty":-12.342996,"median":-6.513434,"eighty":-1.443036,"marketCap":15918720},{"date":"2023-09-01","current":-0.930908,"twenty":-12.279481,"median":-6.507305,"eighty":-1.400387,"marketCap":15829832},{"date":"2023-09-07","current":-0.9532,"twenty":-12.279481,"median":-6.507305,"eighty":-1.339451,"marketCap":16208912},{"date":"2023-09-15","current":-0.799458,"twenty":-12.279481,"median":-6.507305,"eighty":-1.028381,"marketCap":13594571},{"date":"2023-09-22","current":-0.544841,"twenty":-12.279481,"median":-6.455247,"eighty":-0.986118,"marketCap":9264880},{"date":"2023-09-29","current":-0.551575,"twenty":-12.189568,"median":-6.403188,"eighty":-0.977377,"marketCap":9379390},{"date":"2023-10-06","current":-0.518763,"twenty":-12.037502,"median":-6.320693,"eighty":-0.970344,"marketCap":8821415},{"date":"2023-10-13","current":-0.530699,"twenty":-11.976086,"median":-6.247013,"eighty":-0.956072,"marketCap":9024389},{"date":"2023-10-20","current":-0.575911,"twenty":-11.699715,"median":-6.247013,"eighty":-0.93715,"marketCap":9793212},{"date":"2023-10-23","current":-0.575911,"twenty":-11.607592,"median":-6.247013,"eighty":-0.935766,"marketCap":9793212},{"date":"2023-11-03","current":-0.39211,"twenty":-11.454052,"median":-6.205643,"eighty":-0.929985,"marketCap":6667719},{"date":"2023-11-10","current":-0.459259,"twenty":-11.438698,"median":-6.194955,"eighty":-0.92073,"marketCap":7809566},{"date":"2023-11-17","current":-0.390317,"twenty":-11.433836,"median":-6.159301,"eighty":-0.839196,"marketCap":6257237},{"date":"2023-11-24","current":-0.402144,"twenty":-11.390205,"median":-6.151098,"eighty":-0.827299,"marketCap":6446851},{"date":"2023-12-01","current":-0.42372,"twenty":-11.361928,"median":-6.10227,"eighty":-0.805526,"marketCap":6792739},{"date":"2023-12-08","current":-0.428009,"twenty":-11.315866,"median":-6.090838,"eighty":-0.797799,"marketCap":6861499},{"date":"2023-12-15","current":-0.482209,"twenty":-11.185028,"median":-6.067797,"eighty":-0.787784,"marketCap":7730387},{"date":"2023-12-22","current":-0.37173,"twenty":-11.080219,"median":-6.002517,"eighty":-0.7805,"marketCap":5959274},{"date":"2023-12-29","current":-0.506905,"twenty":-11.039738,"median":-5.988209,"eighty":-0.774737,"marketCap":8126282},{"date":"2024-01-05","current":-0.490144,"twenty":-10.994407,"median":-5.986721,"eighty":-0.773619,"marketCap":7857593},{"date":"2024-01-12","current":-0.487408,"twenty":-10.970184,"median":-5.986721,"eighty":-0.764089,"marketCap":7813732},{"date":"2024-01-19","current":-0.454914,"twenty":-10.929162,"median":-5.874148,"eighty":-0.758896,"marketCap":7292817},{"date":"2024-01-26","current":-0.452965,"twenty":-10.829581,"median":-5.726429,"eighty":-0.751007,"marketCap":7261562},{"date":"2024-02-02","current":-0.428919,"twenty":-10.714765,"median":-5.67437,"eighty":-0.72911,"marketCap":6876084},{"date":"2024-02-09","current":-0.378229,"twenty":-10.624938,"median":-5.600708,"eighty":-0.690979,"marketCap":6063456},{"date":"2024-02-16","current":-0.470303,"twenty":-10.59423,"median":-5.518195,"eighty":-0.661662,"marketCap":7539522},{"date":"2024-02-23","current":-0.467912,"twenty":-10.588724,"median":-3.750463,"eighty":-0.651122,"marketCap":7501183},{"date":"2024-03-01","current":-0.519902,"twenty":-10.555264,"median":-3.679026,"eighty":-0.62303,"marketCap":8334648},{"date":"2024-03-08","current":-0.467918,"twenty":-10.486753,"median":-3.607588,"eighty":-0.60253,"marketCap":7501287},{"date":"2024-03-15","current":-0.467912,"twenty":-10.440691,"median":-3.607588,"eighty":-0.583874,"marketCap":7501183},{"date":"2024-03-22","current":-0.466066,"twenty":-10.409983,"median":-3.57187,"eighty":-0.577049,"marketCap":7471595},{"date":"2024-03-28","current":-0.464662,"twenty":-10.348567,"median":-3.536865,"eighty":-0.575543,"marketCap":7449091},{"date":"2024-04-05","current":-0.57144,"twenty":-10.277336,"median":-3.500432,"eighty":-0.575034,"marketCap":9121131},{"date":"2024-04-12","current":-0.499602,"twenty":-10.232538,"median":-3.465071,"eighty":-0.559641,"marketCap":7974474},{"date":"2024-04-19","current":-0.466948,"twenty":-10.210381,"median":-2.953758,"eighty":-0.555795,"marketCap":7453267},{"date":"2024-04-26","current":-0.472826,"twenty":-10.210381,"median":-2.714621,"eighty":-0.546188,"marketCap":7547084},{"date":"2024-05-03","current":-0.451927,"twenty":-10.210381,"median":-2.602107,"eighty":-0.539063,"marketCap":7213511},{"date":"2024-05-10","current":-0.501555,"twenty":-10.21005,"median":-2.572103,"eighty":-0.531663,"marketCap":8005642},{"date":"2024-05-17","current":-0.416074,"twenty":-10.193701,"median":-2.505399,"eighty":-0.520528,"marketCap":6775697},{"date":"2024-05-24","current":-0.419288,"twenty":-10.1323,"median":-2.491379,"eighty":-0.517907,"marketCap":6828026},{"date":"2024-05-31","current":-0.374766,"twenty":-10.127054,"median":-2.488168,"eighty":-0.505605,"marketCap":6103000},{"date":"2024-06-07","current":-0.36451,"twenty":-10.056842,"median":-2.456196,"eighty":-0.501555,"marketCap":5935976},{"date":"2024-06-14","current":-0.365112,"twenty":-10.047676,"median":-2.425835,"eighty":-0.493908,"marketCap":5945783},{"date":"2024-06-21","current":-0.314054,"twenty":-10.006197,"median":-2.408333,"eighty":-0.492726,"marketCap":5114314},{"date":"2024-06-28","current":-0.336969,"twenty":-9.980072,"median":-2.377973,"eighty":-0.490144,"marketCap":5487484},{"date":"2024-07-05","current":-0.331844,"twenty":-9.956506,"median":-2.333681,"eighty":-0.487408,"marketCap":5404024},{"date":"2024-07-12","current":-0.336329,"twenty":-9.912764,"median":-2.294926,"eighty":-0.482209,"marketCap":5477052},{"date":"2024-07-15","current":-0.358751,"twenty":-9.903302,"median":-2.293497,"eighty":-0.482209,"marketCap":5842188},{"date":"2024-08-02","current":-0.320954,"twenty":-9.903302,"median":-2.292069,"eighty":-0.481169,"marketCap":5226672},{"date":"2024-08-09","current":-0.310704,"twenty":-9.891593,"median":-2.279389,"eighty":-0.474405,"marketCap":5059752},{"date":"2024-08-16","current":-0.292199,"twenty":-9.80199,"median":-2.153123,"eighty":-0.473282,"marketCap":4788508},{"date":"2024-08-23","current":-0.299561,"twenty":-9.623984,"median":-2.117225,"eighty":-0.472794,"marketCap":4909164},{"date":"2024-08-30","current":-0.300103,"twenty":-9.596223,"median":-2.088826,"eighty":-0.470393,"marketCap":4918039},{"date":"2024-09-06","current":-0.272682,"twenty":-9.596223,"median":-2.071684,"eighty":-0.467918,"marketCap":4468666},{"date":"2024-09-13","current":-0.251339,"twenty":-9.596223,"median":-2.055611,"eighty":-0.466948,"marketCap":4118899},{"date":"2024-09-20","current":-0.305811,"twenty":-9.556182,"median":-2.005265,"eighty":-0.464662,"marketCap":5011588},{"date":"2024-09-27","current":-0.372708,"twenty":-9.555365,"median":-1.857015,"eighty":-0.464013,"marketCap":6107873},{"date":"2024-10-04","current":-0.333462,"twenty":-9.519453,"median":-1.780577,"eighty":-0.462388,"marketCap":5464719},{"date":"2024-10-11","current":-0.307723,"twenty":-9.514531,"median":-1.762986,"eighty":-0.459259,"marketCap":5042911},{"date":"2024-10-18","current":-0.254206,"twenty":-9.473696,"median":-1.752716,"eighty":-0.454914,"marketCap":4165883},{"date":"2024-10-25","current":-0.257597,"twenty":-9.473696,"median":-1.739733,"eighty":-0.453887,"marketCap":4221452},{"date":"2024-10-31","current":-0.251858,"twenty":-9.448886,"median":-1.696995,"eighty":-0.452009,"marketCap":4127410},{"date":"2024-11-08","current":-0.232092,"twenty":-9.442684,"median":-1.64306,"eighty":-0.451927,"marketCap":3803486},{"date":"2024-11-15","current":-0.264925,"twenty":-9.434826,"median":-1.559122,"eighty":-0.448416,"marketCap":4179209},{"date":"2024-11-22","current":-0.255291,"twenty":-9.400193,"median":-1.53519,"eighty":-0.441407,"marketCap":4027237},{"date":"2024-11-29","current":-0.248066,"twenty":-9.392026,"median":-1.464467,"eighty":-0.436176,"marketCap":3913259},{"date":"2024-12-06","current":-0.22639,"twenty":-9.392026,"median":-1.42857,"eighty":-0.428919,"marketCap":3571324},{"date":"2024-12-13","current":-0.214348,"twenty":-9.376359,"median":-1.339451,"eighty":-0.427079,"marketCap":3381360},{"date":"2024-12-20","current":-0.214348,"twenty":-9.365914,"median":-1.339272,"eighty":-0.42489,"marketCap":3381360},{"date":"2024-12-27","current":-0.223982,"twenty":-9.343691,"median":-1.028151,"eighty":-0.42257,"marketCap":3533331},{"date":"2025-01-03","current":-0.235221,"twenty":-9.310356,"median":-1.010569,"eighty":-0.421624,"marketCap":3710631},{"date":"2025-01-10","current":-0.224785,"twenty":-9.310356,"median":-0.986085,"eighty":-0.419171,"marketCap":3545995},{"date":"2025-01-17","current":-0.196687,"twenty":-9.310356,"median":-0.982799,"eighty":-0.415922,"marketCap":3102746},{"date":"2025-01-24","current":-0.199898,"twenty":-9.293386,"median":-0.974419,"eighty":-0.403234,"marketCap":3153403},{"date":"2025-01-31","current":-0.18063,"twenty":-9.289144,"median":-0.972201,"eighty":-0.402144,"marketCap":2849460},{"date":"2025-02-07","current":-0.1718,"twenty":-9.289144,"median":-0.961273,"eighty":-0.392063,"marketCap":2710153},{"date":"2025-02-14","current":-0.117209,"twenty":-9.289144,"median":-0.955593,"eighty":-0.387742,"marketCap":1848983},{"date":"2025-02-21","current":-0.108378,"twenty":-9.27737,"median":-0.940824,"eighty":-0.3827,"marketCap":1709676},{"date":"2025-02-28","current":-0.097942,"twenty":-9.24551,"median":-0.936135,"eighty":-0.373943,"marketCap":1545040},{"date":"2025-03-07","current":-0.097139,"twenty":-9.219226,"median":-0.930908,"eighty":-0.369851,"marketCap":1532376},{"date":"2025-03-14","current":-0.083491,"twenty":-9.212374,"median":-0.928755,"eighty":-0.36451,"marketCap":1317084},{"date":"2025-03-21","current":-0.094731,"twenty":-9.173159,"median":-0.922298,"eighty":-0.358765,"marketCap":1494383},{"date":"2025-03-28","current":-0.256818,"twenty":-9.140169,"median":-0.914919,"eighty":-0.347994,"marketCap":3570947},{"date":"2025-04-04","current":-0.24709,"twenty":-9.135604,"median":-0.83876,"eighty":-0.336713,"marketCap":3435684},{"date":"2025-04-11","current":-0.311294,"twenty":-9.135604,"median":-0.828668,"eighty":-0.333105,"marketCap":4328420},{"date":"2025-04-17","current":-0.266546,"twenty":-9.074188,"median":-0.824365,"eighty":-0.330695,"marketCap":3706210},{"date":"2025-04-25","current":-0.334642,"twenty":-8.982065,"median":-0.805313,"eighty":-0.326015,"marketCap":4653052},{"date":"2025-05-02","current":-0.29573,"twenty":-8.951357,"median":-0.80139,"eighty":-0.323462,"marketCap":4111999},{"date":"2025-05-09","current":-0.417852,"twenty":-8.874587,"median":-0.792023,"eighty":-0.321722,"marketCap":5810061}],"updateTime":1747050008618}}}